Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
作者信息
Azad Tej D, Bettegowda Chetan
机构信息
Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.
出版信息
Neuro Oncol. 2022 Aug 1;24(8):1375-1376. doi: 10.1093/neuonc/noac076.
Abstract
摘要
相似文献
1
Longitudinal monitoring of diffuse midline glioma using liquid biopsy.使用液体活检对弥漫性中线胶质瘤进行纵向监测。
Neuro Oncol. 2022 Aug 1;24(8):1375-1376. doi: 10.1093/neuonc/noac076.
2
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.连续的 H3K27M 无细胞肿瘤 DNA（cf-tDNA）检测可预测弥漫中线胶质瘤患者对 ONC201 治疗的反应和进展。
Neuro Oncol. 2022 Aug 1;24(8):1366-1374. doi: 10.1093/neuonc/noac030.
3
ONC201 and ONC206: Metabolically ClipPing the wings of diffuse midline glioma.ONC201和ONC206：代谢性限制弥漫性中线胶质瘤的发展
Neuro Oncol. 2022 Sep 1;24(9):1452-1453. doi: 10.1093/neuonc/noac103.
4
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients' management: Close to the clinic?脑脊髓液肿瘤 DNA 进行液体活检在胶质瘤患者管理中的应用：接近临床？
Crit Rev Oncol Hematol. 2020 Feb;146:102879. doi: 10.1016/j.critrevonc.2020.102879. Epub 2020 Jan 24.
5
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.接受选择性 DRD2 拮抗剂 ONC201 治疗的小儿和成人 H3 K27M 突变型弥漫中线脑胶质瘤。
J Neurooncol. 2019 Oct;145(1):97-105. doi: 10.1007/s11060-019-03271-3. Epub 2019 Aug 27.
6
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.利用患者衍生的液体活检对儿科弥漫性中线胶质瘤进行具有临床相关性和微创性的肿瘤监测。
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859. doi: 10.1158/1078-0432.CCR-18-1345. Epub 2018 Oct 15.
7
Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.应用基于芯片的数字 PCR 系统对脑脊液中 IDH、TERT 和 H3 突变进行分析，实现弥漫性胶质瘤的分子诊断。
J Neurooncol. 2021 Mar;152(1):47-54. doi: 10.1007/s11060-020-03682-7. Epub 2021 Jan 8.
8
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.H3K27M 突变型胶质瘤的靶向治疗与治疗监测
Curr Oncol Rep. 2020 Feb 6;22(2):19. doi: 10.1007/s11912-020-0877-0.
9
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma.检测弥漫性中线胶质瘤患儿脑脊液来源肿瘤 DNA 中的组蛋白 H3 突变。
Acta Neuropathol Commun. 2017 Apr 17;5(1):28. doi: 10.1186/s40478-017-0436-6.
10
Diffuse Midline Gliomas without the H3 K27M Mutation: Surgical Biopsy is Needed to Better our Diagnostic Understanding.无H3 K27M突变的弥漫性中线胶质瘤：需要手术活检以加深我们的诊断理解。
World Neurosurg. 2020 May;137:472-473. doi: 10.1016/j.wneu.2020.02.134.
引用本文的文献
1
Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method.在脑肿瘤患者的液体活检中检测H3F3A K27M或BRAF V600E作为诊断和监测生物标志物：肿瘤定位和采样方法的影响
Acta Neuropathol. 2025 Jan 3;149(1):5. doi: 10.1007/s00401-024-02842-7.
2
Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas.成人脑胶质瘤的脑脊液液体活检评估。
Curr Oncol Rep. 2024 Apr;26(4):377-390. doi: 10.1007/s11912-024-01517-6. Epub 2024 Mar 15.
3
Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment.解读弥漫性中线胶质瘤：发病机制、诊断与治疗的全面综述
Cancers (Basel). 2023 Oct 6;15(19):4869. doi: 10.3390/cancers15194869.
本文引用的文献
1
Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.连续的 H3K27M 无细胞肿瘤 DNA（cf-tDNA）检测可预测弥漫中线胶质瘤患者对 ONC201 治疗的反应和进展。
Neuro Oncol. 2022 Aug 1;24(8):1366-1374. doi: 10.1093/neuonc/noac030.
2
Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR.利用 ddPCR 对小儿弥漫性中线脑胶质瘤进行液体活检的标准化。
Sci Rep. 2021 Mar 3;11(1):5098. doi: 10.1038/s41598-021-84513-1.
3
A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.cobas® EGFR Mutation Test v2 伴随诊断检测用于非小细胞肺癌患者一线治疗的简介。
Expert Rev Mol Diagn. 2020 Jun;20(6):575-582. doi: 10.1080/14737159.2020.1724094. Epub 2020 Feb 20.
4
Liquid biopsy for pediatric diffuse midline glioma: a review of circulating tumor DNA and cerebrospinal fluid tumor DNA.液体活检在小儿弥漫性中线脑胶质瘤中的应用：循环肿瘤 DNA 和脑脊液肿瘤 DNA 的综述。
Neurosurg Focus. 2020 Jan 1;48(1):E9. doi: 10.3171/2019.9.FOCUS19699.
5
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium.一项针对弥漫性内在脑桥胶质瘤患儿的精准医学试验-PNOC003：来自太平洋儿科神经肿瘤学联盟的报告。
Int J Cancer. 2019 Oct 1;145(7):1889-1901. doi: 10.1002/ijc.32258. Epub 2019 Apr 3.
6
Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.利用患者衍生的液体活检对儿科弥漫性中线胶质瘤进行具有临床相关性和微创性的肿瘤监测。
Clin Cancer Res. 2018 Dec 1;24(23):5850-5859. doi: 10.1158/1078-0432.CCR-18-1345. Epub 2018 Oct 15.
7
Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.弥漫性高级别胶质瘤伴 H3 K27M 突变无论肿瘤位置如何，预后均较差。
Neuro Oncol. 2018 Jan 10;20(1):123-131. doi: 10.1093/neuonc/nox149.
8
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.K27M 突变的组蛋白 H3.3 定义了具有临床和生物学特征的不同亚组的儿童弥漫性内在脑桥胶质瘤。
Acta Neuropathol. 2012 Sep;124(3):439-47. doi: 10.1007/s00401-012-0998-0. Epub 2012 Jun 3.
9
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.儿童弥漫性内在脑桥神经胶质瘤和非脑干部位神经胶质瘤中的体干细胞组蛋白 H3 改变。
Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102.
Zotero 插件